Instruction file imported from fjkiani/caspro (.cursor/rules/slide-component-extraction.mdc). Copyright stays with the author.

Slide Component Extraction Guide

Source File Analysis

drugDevelopmentSlide.tsx contains our complete drug development doctrine in slide format. This file serves as the blueprint for our interactive platform components.

Extraction Priority Matrix

Based on the three-stage drug development doctrine from DD.md

Tier 1: Core Discovery Campaign Demos (Immediate Homepage Integration)

Stage 1: Target Validation Demo

Component: VUSConquestDemo (combines ZetaScoreGauge + DependencyAnalysis)

Location: Lines 160-180, 391-413 in drugDevelopmentSlide.tsx
Purpose: Demonstrate 60-second in-silico conquest replacing months of exploratory validation
Extract to: src/components/drug-development/apis/TargetValidationDemo.tsx
APIs: /predict_variant_impact + /predict_gene_essentiality
Problem: "Exploratory phase requiring months or years to collect scientific data"
Solution: "Immediate, evidence-backed 'Yes/GO' verdict on any proposed target"
Evidence:
- ≈0.95 AUROC on BRCA1 (Evo 2 Paper, Methods 4.3.16)
- Matches experimental CRISPR screens (Evo 2 Paper, Fig. 2J)
- New SOTA on ClinVar benchmark (Evo 2 Paper, Fig. 3C)
Use Case: BRCA1/2 VUS Crisis - transforming clinical question marks into actionable intelligence

Stage 2: Lead Engineering Demo

Component: ZetaForgeDemo (TherapeuticGenerator)

Location: Lines 450-478 (DoctrineLeadDiscoverySlide)
Purpose: Show "we don't discover leads; we engineer them" - making screening obsolete
Extract to: src/components/drug-development/apis/ZetaForgeDemo.tsx
APIs: /generate_optimized_guide_rna, /generate_therapeutic_protein
Problem: "Screen hundreds of thousands to millions of molecules for action on drug target"
Solution: "Generative AI Zeta Forge makes entire screening process obsolete"
Evidence:
- ~70% Pfam-hit rate vs ~18% previous models (Evo 2 Paper, Fig. 5H)
- AlphaFold 3 validated 3D structures (Evo 2 Paper, Fig. 5F)
Key Principle: "Optimization embedded in design process - engineer for efficacy and safety from first principles"

Stage 3: Pre-Clinical Confirmation Demo

Component: InSilicoTrialDemo (FunctionalityPredictor + Structural Validation)

Location: Lines 547-571 (PredictProteinFunctionalitySlide_Part1)
Purpose: Shift confirmation from expensive wet-lab to near-zero-cost in-silico trial
Extract to: src/components/drug-development/apis/InSilicoTrialDemo.tsx
APIs: /predict_protein_functionality_change + Zeta Boltz structural engine
Problem: "Expensive wet-lab confirmation - final gate before human testing"
Solution: "Complete IND-ready dossier with high certainty, transforming pre-clinical stage from gate into formality"
Evidence:
- Strong correlation with DMS assays (Evo 2 Paper, Fig. 2E)
- AlphaFold 3 structural oracle integration (Evo 2 Paper, Fig. 5F)
Deliverable: "Cellular-level therapeutic effect simulation + physical proof of mechanism"

Tier 2: Supporting Visual Components

5. EvidenceCard Component

Location: Lines 182-196
Purpose: Standardized evidence metric display
Extract to: src/components/drug-development/evidence/EvidenceCard.tsx
Usage: Show performance metrics with sources

6. StatCard Component

Location: Lines 108-113
Purpose: Display key statistics (success rates, costs, timelines)
Extract to: src/components/drug-development/evidence/StatCard.tsx
Usage: Homepage problem statement ($2.6B, <5% success rate)

7. ScatterPlot Component

Location: Lines 205-225
Purpose: Show correlation between predictions and experimental results
Extract to: src/components/drug-development/evidence/CorrelationChart.tsx
Usage: Prove in-silico accuracy

Tier 3: Narrative Components

8. DoctrineComparison Component

Location: Lines 123-151
Purpose: Traditional vs CrisPRO approach comparison
Extract to: src/components/drug-development/narrative/DoctrineComparison.tsx
Usage: Educational content, about pages

9. PathOutcome Component

Location: Lines 198-203
Purpose: Show verified outcomes with color coding
Extract to: src/components/drug-development/evidence/PathOutcome.tsx
Usage: Before/after result displays

Component Extraction Standards

File Structure

src/components/drug-development/
├── apis/                    # Live API demonstrations
│   ├── ZetaScoreDemo.tsx
│   ├── EssentialityDemo.tsx
│   ├── GenerativeDemo.tsx
│   └── BindingDemo.tsx
├── evidence/               # Performance metrics
│   ├── EvidenceCard.tsx
│   ├── StatCard.tsx
│   └── CorrelationChart.tsx
├── narrative/              # Educational comparisons
│   └── DoctrineComparison.tsx
└── shared/                 # Reusable utilities
    ├── SlideLayout.tsx
    └── AnimationComponents.tsx

Component Interface Pattern

Aligned with DD.md doctrine structure

interface DrugDevelopmentStage {
  // Stage identification
  stage: 'target-validation' | 'lead-engineering' | 'preclinical-confirmation';
  stageNumber: 1 | 2 | 3;
  
  // API endpoints for this stage
  apis: string[];
  
  // Problem-solution-evidence narrative
  traditional: {
    approach: string;
    timeframe: string;
    cost: string;
    problems: string[];
  };
  
  doctrine: {
    approach: string;
    timeframe: string; // e.g., "60-second conquest"
    advantage: string;
    deliverable: string;
  };
  
  // Evidence protocol from Evo 2 paper
  evidence: Array<{
    metric: string;
    description: string;
    source: string; // e.g., "Evo 2 Paper, Fig. 3C"
  }>;
  
  // Business impact
  impact: {
    oncologists: string[];
    biotechs: string[];
  };
  
  // Interactive demo configuration
  demo: {
    component: React.ComponentType;
    title: string;
    description: string;
    features: string[];
    useCaseSpotlight?: {
      title: string;
      problem: string;
      solution: string;
      impact: string;
    };
  };
}

Animation Preservation

When extracting components, preserve these key animations:

ZetaScoreGauge: Needle rotation animation (lines 166-169)
Key-Lock Simulation: X-axis movement for binding (lines 587-591, 614-616)
Scatter Plot: Sequential point appearance (lines 219-220)
Block Tower: Collapse animation for Achilles' heel (lines 438-441)

Data Dependencies

Extract these data structures to src/data/drug-development/:

API Configurations

export const API_ENDPOINTS = {
  VARIANT_IMPACT: '/predict_variant_impact',
  GENE_ESSENTIALITY: '/predict_gene_essentiality', 
  GENERATE_GUIDE_RNA: '/generate_optimized_guide_rna',
  GENERATE_PROTEIN: '/generate_therapeutic_protein',
  FUNCTIONALITY_CHANGE: '/predict_protein_functionality_change'
};

Evidence Metrics

export const EVIDENCE_METRICS = {
  BRCA_AUROC: { value: '≈0.95', label: 'AUROC', source: 'Evo 2 Paper, Methods 4.3.16' },
  PFAM_HIT_RATE: { value: '~70%', label: 'Pfam-hit rate', source: 'Evo 2 Paper, Fig. 5H' },
  // ... other metrics
};

Integration Checklist

For each extracted component:

Usage Priority & Integration Strategy

1. Homepage Transformation

Replace LiveDemoSection.tsx with three-stage doctrine:

Hero Message: "Transform drug development from a $2.6B gamble into deterministic engineering"

Three Live Demos:

Target Validation: "60-Second Conquest" - VUS → Verdict with 95% certainty
Lead Engineering: "Zeta Forge" - Engineer don't discover, screening obsolete
Pre-Clinical Confirmation: "In-Silico Trial" - Wet lab → computational verdict

Evidence Integration: Each demo shows Problem → CrisPRO Doctrine → Evidence Protocol pattern

2. Platform Pages

/drug-development/target-validation - Full Stage 1 workflow
/drug-development/lead-engineering - Full Stage 2 workflow
/drug-development/preclinical-confirmation - Full Stage 3 workflow
Each page includes business impact for oncologists and biotechs

3. About/Evidence Pages

BRCA1/2 VUS Crisis spotlight as primary use case
Phase II advantages for clinical trials (safety, efficacy, pivotal)
90% failure rate inversion through discovery transformation

4. Marketing/Sales Materials

Problem Metrics: <5% success rate, $2.6B cost, 10-15 years
Solution Metrics: 60-second conquest, 95% AUROC, 70% Pfam-hit rate
Business Impact: Precision patient selection, R&D de-risking, IND-ready dossiers

Success Metrics

Understanding: Can visitors immediately grasp how we solve the $2.6B problem?
Engagement: Do users interact with drug development stages vs generic demos?
Conversion: Do leads understand our competitive advantage in replacing ambiguity with mathematical certainty?

This extraction plan transforms our slide deck into a living, interactive platform that demonstrates our drug development doctrine at every touchpoint, replacing the traditional high-risk gamble with deterministic engineering.

slide-component-extraction

About